BAMBUSA THERAPEUTICS Mediaroom - PR Newswire APAC

Search

BAMBUSA THERAPEUTICS

Latest News

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beg...

2026-07-27 18:00 2029

Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board

Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the com...

2026-07-15 21:00 6015

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commerc...

2026-06-15 19:00 3712

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commerc...

2026-05-18 21:15 7129

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody tar...

2026-04-30 20:00 5801

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody tar...

2026-04-01 21:00 7924

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep experti...

2026-03-19 20:30 8292

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology com...

2026-01-06 22:30 2542

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biot...

2025-11-17 22:15 3651

Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinica...

2025-09-25 22:04 3926

Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

* Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy an...

2025-05-30 21:30 4310

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and do...

2025-02-28 22:58 5745

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company...

2025-02-14 21:56 4346

Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation

BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on...

2024-09-09 21:09 2571